Amgen Stock And The Price Of A Promise

Amgen recently raised its full-year revenue guidance, typically a positive signal, but its stock has not seen a significant celebratory pop. While the company's current performance is strong with multiple products showing double-digit growth, the market appears to have already factored this in. Investors are now looking for the next major catalyst, particularly from Amgen's drug pipeline, especially its experimental weight-loss treatment MariTide, to justify further stock appreciation.